Overview

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Status:
Terminated
Trial end date:
2013-03-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated participants with follicular lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Treatments:
Antibodies, Monoclonal
Rituximab